JP2013500269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500269A5 JP2013500269A5 JP2012521872A JP2012521872A JP2013500269A5 JP 2013500269 A5 JP2013500269 A5 JP 2013500269A5 JP 2012521872 A JP2012521872 A JP 2012521872A JP 2012521872 A JP2012521872 A JP 2012521872A JP 2013500269 A5 JP2013500269 A5 JP 2013500269A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- αvβ5 integrin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006495 integrins Human genes 0.000 claims description 26
- 108010044426 integrins Proteins 0.000 claims description 26
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 229940123038 Integrin antagonist Drugs 0.000 claims description 3
- 102000004264 Osteopontin Human genes 0.000 claims description 3
- 108010081689 Osteopontin Proteins 0.000 claims description 3
- 102000007000 Tenascin Human genes 0.000 claims description 3
- 108010008125 Tenascin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108700025771 adenovirus penton Proteins 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 239000004041 inotropic agent Substances 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 102000016359 Fibronectins Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22841609P | 2009-07-24 | 2009-07-24 | |
| US61/228,416 | 2009-07-24 | ||
| PCT/US2010/043211 WO2011011775A1 (en) | 2009-07-24 | 2010-07-26 | Methods and compositions for treating and preventing disease associated with avb5 integrin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500269A JP2013500269A (ja) | 2013-01-07 |
| JP2013500269A5 true JP2013500269A5 (enExample) | 2014-05-08 |
| JP5755647B2 JP5755647B2 (ja) | 2015-07-29 |
Family
ID=43499449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521872A Expired - Fee Related JP5755647B2 (ja) | 2009-07-24 | 2010-07-26 | αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10087252B2 (enExample) |
| EP (1) | EP2456460A4 (enExample) |
| JP (1) | JP5755647B2 (enExample) |
| KR (1) | KR101752515B1 (enExample) |
| CN (1) | CN102481347A (enExample) |
| AU (1) | AU2010275367B2 (enExample) |
| BR (1) | BR112012001463A2 (enExample) |
| CA (1) | CA2767409C (enExample) |
| IL (1) | IL217406A (enExample) |
| IN (1) | IN2012DN00303A (enExample) |
| WO (1) | WO2011011775A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201215414D0 (en) * | 2012-08-30 | 2012-10-17 | Isis Innovation | Composition and use |
| HK1219740A1 (zh) * | 2013-03-15 | 2017-04-13 | Biogen Ma Inc. | 使用抗αVβ5抗体治疗和预防急性肾损伤 |
| EP3191519A1 (en) * | 2014-09-12 | 2017-07-19 | Biogen MA Inc. | Humanized anti-alpha v beta 5 antibodies and uses thereof |
| CN109476632A (zh) * | 2016-07-05 | 2019-03-15 | 洛克菲勒大学 | 四氢萘啶戊酰胺整联蛋白拮抗剂 |
| BR112021020116A2 (pt) * | 2019-04-08 | 2021-12-07 | Biogen Ma Inc | Anticorpos anti-integrina e usos dos mesmos |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5527679A (en) | 1991-05-01 | 1996-06-18 | Dana Farber Cancer Institute | β5 protein and DNA encoding the same |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6291196B1 (en) | 1992-01-31 | 2001-09-18 | Research Corporation Technologies, Inc. | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US7053041B1 (en) | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
| UA60311C2 (uk) | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| ATE410179T1 (de) | 1997-08-08 | 2008-10-15 | Univ California | Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| PL347976A1 (en) | 1999-09-29 | 2002-05-06 | Ortho Mcneil Pharm Inc | Isonipecotamides for the treatment of integrin−mediated disorders |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CA2397194C (en) | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Alpha v integrin receptor antagonists |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| JP4039856B2 (ja) | 2000-02-03 | 2008-01-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インテグリン発現阻害剤 |
| US20020004042A1 (en) | 2000-04-18 | 2002-01-10 | Factor Phillip H. | Gene therapy for pulmonary edema using adenovirus vectors encoding a beta2adrenergic receptor gene |
| US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| US20020072500A1 (en) | 2000-09-27 | 2002-06-13 | Thomas Rogers | Hydroxy acid integrin antagonists |
| AU2002239435B2 (en) | 2000-10-24 | 2005-10-27 | Merck & Co., Inc. | Dibenzoxazepine alpha v integrin receptor antagonist |
| WO2002059300A2 (en) | 2000-12-28 | 2002-08-01 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| CA2443378A1 (en) | 2001-04-04 | 2002-10-17 | Allergan, Inc. | Methods of screening and using inhibitors of angiogenesis |
| JP2004529918A (ja) | 2001-04-09 | 2004-09-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物 |
| US20040019206A1 (en) | 2001-09-27 | 2004-01-29 | Peter Ruminiski | Lactone integrin antagonists |
| US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US20040077684A1 (en) | 2002-08-16 | 2004-04-22 | Bart De Corte | Piperidinyl compounds that selectively bind integrins |
| EP2394662B1 (en) * | 2004-04-02 | 2018-03-21 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin |
| JP2012512170A (ja) * | 2008-12-12 | 2012-05-31 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 血管バリア機能の促進および肺線維症の治療する組成物および方法 |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| HK1219740A1 (zh) * | 2013-03-15 | 2017-04-13 | Biogen Ma Inc. | 使用抗αVβ5抗体治疗和预防急性肾损伤 |
| EP3191519A1 (en) * | 2014-09-12 | 2017-07-19 | Biogen MA Inc. | Humanized anti-alpha v beta 5 antibodies and uses thereof |
-
2010
- 2010-07-26 US US13/386,323 patent/US10087252B2/en active Active
- 2010-07-26 EP EP10803008A patent/EP2456460A4/en not_active Withdrawn
- 2010-07-26 JP JP2012521872A patent/JP5755647B2/ja not_active Expired - Fee Related
- 2010-07-26 AU AU2010275367A patent/AU2010275367B2/en not_active Ceased
- 2010-07-26 CN CN2010800333673A patent/CN102481347A/zh active Pending
- 2010-07-26 KR KR1020127003723A patent/KR101752515B1/ko not_active Expired - Fee Related
- 2010-07-26 CA CA2767409A patent/CA2767409C/en not_active Expired - Fee Related
- 2010-07-26 IN IN303DEN2012 patent/IN2012DN00303A/en unknown
- 2010-07-26 WO PCT/US2010/043211 patent/WO2011011775A1/en not_active Ceased
- 2010-07-26 BR BR112012001463A patent/BR112012001463A2/pt not_active Application Discontinuation
-
2012
- 2012-01-05 IL IL217406A patent/IL217406A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Slack et al. | Emerging therapeutic opportunities for integrin inhibitors | |
| Beavers et al. | Cardio-oncology drug interactions: a scientific statement from the American Heart Association | |
| Chavakis et al. | Role of β2-integrins for homing and neovascularization capacity of endothelial progenitor cells | |
| van der Holt et al. | The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | |
| JP2013500269A5 (enExample) | ||
| Rashidi et al. | Targeting the microenvironment in acute myeloid leukemia | |
| Eisen et al. | Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | |
| Mohamed et al. | Therapeutic advances in the treatment of SLE | |
| Rice et al. | Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale | |
| Reardon et al. | Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme | |
| Arias‐Mejias et al. | The role of integrins in melanoma: a review | |
| FI118842B (fi) | Menetelmä terapeuttisesti tehokkaan aineen, joka sitoutuu alfa4beeta1:een, tai sen ligandin, valitsemiseksi käytettäväksi lymfosyyttien migraation inhiboimiseksi vaskulaaristen endoteelisolukerrosten | |
| CA2989144A1 (en) | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways | |
| Cantor et al. | Integrin αvβ6 sets the stage for colorectal cancer metastasis | |
| JP2020023499A (ja) | 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療 | |
| JP2013531655A5 (enExample) | ||
| Denmark et al. | Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update | |
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| Guijarro-Muñoz et al. | The axonal repellent Slit2 inhibits pericyte migration: potential implications in angiogenesis | |
| JP2008509086A5 (enExample) | ||
| Ruseva et al. | Tumor suppressor KAI1 affects integrin αvβ3-mediated ovarian cancer cell adhesion, motility, and proliferation | |
| HRP20230742T1 (hr) | Lrrc33 inhibitori i njihova uporaba | |
| Lin et al. | Inhibition of endothelial SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), a novel VEGFR2 (vascular endothelial growth factor receptor 2) coreceptor, suppresses tumor angiogenesis | |
| Babar et al. | Anti-HER2 cancer therapy and cardiotoxicity | |
| US11760803B2 (en) | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |